- Molecular NameOxycodone
- SynonymDihydrohydroxycodeinone; Dihydrohydroxycondeinone; Dihydrone; Oxicodona [INN-Spanish]; oxycodone; Oxycodone Hcl; Oxycodone Hydrochloride; Oxycodonum [INN-Latin]; PTI-821
- Weight315.369
- Drugbank_IDDB00497
- ACS_NO76-42-6
- Show 3D model
- LogP (experiment)0.7
- LogP (predicted, AB/LogP v2.0)0.5
- pka8.9
- LogD (pH=7, predicted)-0.59
- Solubility (experiment)100 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.57
- LogSw (predicted, AB/LogsW2.0)11.5
- Sw (mg/ml) (predicted, ACD/Labs)1.48
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds1
- TPSA59.0
- StatusFDA approved
- AdministrationN/A
- PharmacologyThe main active ingredient in a number of oral medications commonly prescribed for the relief of moderate to severe pain.
- Absorption_value60.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability60.0
- Protein binding45.0
- Volume of distribution (VD)2.3 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmOxycodone is metabolized primarily by CYP3A4/5, with a minor contribution from CYP2D6. Oxymorphone is an active metabolite produced by CYP2D6-mediated O-dealkylation.
- Half life2.6 h
- ExcretionOxycodone and its metabolites are mainly excreted in the urine and sweat; therefore, it accumulates in patients with renal impairment.
- Urinary ExcretionN/A
- Clerance12.4 ml/min/kg
- Toxicityrespiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.
- LD50 (rat)N/A
- LD50 (mouse)N/A